GR 63799

Drug Profile

GR 63799

Alternative Names: GR 63799X

Latest Information Update: 13 Jun 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Nonindustrial source
  • Class Antiulcers
  • Mechanism of Action Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Peptic ulcer; Reperfusion injury

Most Recent Events

  • 04 Dec 1998 Preclinical development for Reperfusion injury in United Kingdom (Unknown route)
  • 04 Dec 1998 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 20 Jun 1995 Discontinued-I for Peptic ulcer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top